Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. It has proved beneficial in treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates activity against malignant cells expr...

Full description

Saved in:
Bibliographic Details
Main Authors: Uziel, O, Fenig, E, Nordenberg, J, Beery, E, Reshef, H, Sandbank, J, Birenbaum, M, Bakhanashvili, M, Yerushalmi, R, Luria, D, Lahav, M
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2005
Subjects:
Translational Therapeutics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361771/
https://ncbi.nlm.nih.gov/pubmed/15870711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602592
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items